Bridgebio Oncology Therapeutics, Stock Market Value
| BBOT Stock | 12.71 0.38 3.08% |
| Symbol | BridgeBio |
BridgeBio Oncology Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Oncology. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.11) |
The market value of BridgeBio Oncology is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Oncology's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Oncology's market value can be influenced by many factors that don't directly affect BridgeBio Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BridgeBio Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BridgeBio Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BridgeBio Oncology.
| 11/29/2025 |
| 12/29/2025 |
If you would invest 0.00 in BridgeBio Oncology on November 29, 2025 and sell it all today you would earn a total of 0.00 from holding BridgeBio Oncology Therapeutics, or generate 0.0% return on investment in BridgeBio Oncology over 30 days. BridgeBio Oncology is related to or competes with Estrella Immunopharma, VTv Therapeutics, Telomir Pharmaceuticals,, Fortress Biotech, ImmuCell, Mersana Therapeutics, and BioXcel Therapeutics. BridgeBio Oncology is entity of United States More
BridgeBio Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BridgeBio Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BridgeBio Oncology Therapeutics, upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.03 | |||
| Information Ratio | 0.0279 | |||
| Maximum Drawdown | 23.32 | |||
| Value At Risk | (4.64) | |||
| Potential Upside | 5.51 |
BridgeBio Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BridgeBio Oncology's standard deviation. In reality, there are many statistical measures that can use BridgeBio Oncology historical prices to predict the future BridgeBio Oncology's volatility.| Risk Adjusted Performance | 0.043 | |||
| Jensen Alpha | 0.1317 | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | 0.0364 | |||
| Treynor Ratio | 0.2603 |
BridgeBio Oncology Backtested Returns
Currently, BridgeBio Oncology Therapeutics, is somewhat reliable. BridgeBio Oncology secures Sharpe Ratio (or Efficiency) of 0.0438, which signifies that the company had a 0.0438 % return per unit of risk over the last 3 months. We have found thirty technical indicators for BridgeBio Oncology Therapeutics,, which you can use to evaluate the volatility of the firm. Please confirm BridgeBio Oncology's Mean Deviation of 2.93, downside deviation of 3.03, and Risk Adjusted Performance of 0.043 to double-check if the risk estimate we provide is consistent with the expected return of 0.18%. BridgeBio Oncology has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BridgeBio Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding BridgeBio Oncology is expected to be smaller as well. BridgeBio Oncology right now shows a risk of 4.0%. Please confirm BridgeBio Oncology potential upside, and the relationship between the total risk alpha and kurtosis , to decide if BridgeBio Oncology will be following its price patterns.
Auto-correlation | 0.60 |
Good predictability
BridgeBio Oncology Therapeutics, has good predictability. Overlapping area represents the amount of predictability between BridgeBio Oncology time series from 29th of November 2025 to 14th of December 2025 and 14th of December 2025 to 29th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BridgeBio Oncology price movement. The serial correlation of 0.6 indicates that roughly 60.0% of current BridgeBio Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.6 | |
| Spearman Rank Test | 0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
BridgeBio Oncology lagged returns against current returns
Autocorrelation, which is BridgeBio Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BridgeBio Oncology's stock expected returns. We can calculate the autocorrelation of BridgeBio Oncology returns to help us make a trade decision. For example, suppose you find that BridgeBio Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
BridgeBio Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BridgeBio Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BridgeBio Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BridgeBio Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
BridgeBio Oncology Lagged Returns
When evaluating BridgeBio Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BridgeBio Oncology stock have on its future price. BridgeBio Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BridgeBio Oncology autocorrelation shows the relationship between BridgeBio Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in BridgeBio Oncology Therapeutics,.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BridgeBio Stock Analysis
When running BridgeBio Oncology's price analysis, check to measure BridgeBio Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Oncology is operating at the current time. Most of BridgeBio Oncology's value examination focuses on studying past and present price action to predict the probability of BridgeBio Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Oncology's price. Additionally, you may evaluate how the addition of BridgeBio Oncology to your portfolios can decrease your overall portfolio volatility.